BIO-CAT Microbials, a manufacturer of probiotics, recently published a paper on its proprietary Bacillus strain, Optibiome, appearing in Gut Microbes. The paper focused on the results of a randomized, double-blind, placebo-controlled clinical trial executed in collaboration with Biofortis Inc., a subsidiary of Mérieux NutriSciences.
 
In the study, the probiotic strain was administered to 76 healthy adults daily for six weeks and took part in a questionnaire which they used to record various gastrointestinal symptoms, such as bowel habits and stool consistency. The researchers also recorded circulating intestinal permeability markers, circulating inflammatory markers, lipid profiles, and sleep quality. Participants saw a significant improvement in burping and bloating after the six-week intervention period. The authors concluded that the probiotic was well-tolerated and appeared to be a safe strategy to alleviate gas-related gastrointestinal symptoms in healthy adults. Additionally, a manuscript describing the safety of the probiotic strain was published earlier in 2022.
 
BIO-CAT produces probiotics for the dietary supplement industry under exclusive licensing agreements, and also produce nine strains approved by the Association of American Feed Control Officials (AAFCO) for use in the companion and production animal nutrition markets.
 
The company also recently announced a capital expansion in Troy, Virginia, adding manufacturing redundancy and significantly expanding capacity, with completion anticipated in 2023.
 
BIO-CAT and BIO-CAT Microbials will be attending SupplySide West in Las Vegas, presenting information on the latest Optibiome probiotic and its overall strain development capabilities and best in class fermentation processes.